{
  "disease_name": "Multiple myeloma",
  "synonyms": [
    "Plasma cell myeloma",
    "Myeloma"
  ],
  "summary": "A malignant neoplasm of clonal plasma cells producing monoclonal immunoglobulins or light chains, leading to bone destruction, anemia, renal dysfunction, and immunodeficiency; typically arises from MGUS/SMM progression and is treatable but generally incurable.",
  "causes": [
    "Immunoglobulin heavy chain (IGH) translocations",
    "t(11;14)(q13;q32) CCND1-IGH",
    "t(4;14)(p16;q32) FGFR3/MMSET-IGH",
    "t(14;16)(q32;q23) MAF-IGH",
    "t(14;20)(q32;q11) MAFB-IGH",
    "1q21 amplification (CKS1B)",
    "Deletion 13q",
    "Deletion 17p (TP53)",
    "Progression from MGUS/SMM"
  ],
  "risk_factors": [
    "Older age",
    "Male sex",
    "African ancestry",
    "Obesity",
    "Ionizing radiation exposure",
    "Family history",
    "Occupational exposure to aromatic hydrocarbons (e.g., benzene)"
  ],
  "symptoms": [
    "Bone pain (spine, ribs)",
    "Pathologic fractures",
    "Fatigue",
    "Anemia",
    "Recurrent infections",
    "Renal insufficiency",
    "Hypercalcemia",
    "Weight loss",
    "Neurological symptoms (e.g., weakness, confusion)"
  ],
  "diagnosis": [
    "Serum protein electrophoresis (SPEP)",
    "Urine protein electrophoresis (UPEP)",
    "Immunofixation (IFE)",
    "Serum free light chain assay",
    "Bone marrow biopsy (clonal plasma cells)",
    "Skeletal survey / low-dose whole-body CT",
    "MRI or PET-CT for lesions",
    "Beta-2 microglobulin and albumin (ISS/R-ISS staging)",
    "Myeloma-defining events (IMWG biomarkers)"
  ],
  "treatments": [
    "Proteasome inhibitors (bortezomib, carfilzomib, ixazomib)",
    "IMiDs (lenalidomide, thalidomide, pomalidomide)",
    "Corticosteroids (dexamethasone)",
    "Anti-CD38 monoclonal antibodies (daratumumab, isatuximab)",
    "SLAMF7 antibody (elotuzumab)",
    "BCMA-targeted CAR-T (idecabtagene vicleucel, ciltacabtagene autoleucel)",
    "BCMA bispecific antibodies (teclistamab, elranatamab, talquetamab)",
    "Belantamab mafodotin (anti-BCMA ADC)",
    "Autologous stem cell transplant (ASCT)",
    "Bisphosphonates (zoledronic acid, pamidronate) or denosumab",
    "Radiation therapy (palliation of bone lesions)"
  ],
  "related_genes": [
    "CCND1",
    "FGFR3",
    "NSD2 (WHSC1/MMSET)",
    "MAF",
    "MAFB",
    "TP53",
    "KRAS",
    "NRAS",
    "BRAF",
    "DIS3",
    "FAM46C",
    "ATM",
    "CKS1B"
  ],
  "subtypes": [
    {
      "name": "Hyperdiploid multiple myeloma",
      "typical_patients": "Older adults; trisomies of odd-numbered chromosomes",
      "five_year_survival": "≈65–70%",
      "common_treatments": [
        "Proteasome inhibitor–IMiD–steroid triplets",
        "ASCT (eligible)",
        "Maintenance lenalidomide"
      ]
    },
    {
      "name": "t(11;14) myeloma (CCND1)",
      "typical_patients": "Adults; ~15–20% of cases; may respond to BCL2 inhibition",
      "five_year_survival": "≈60–70%",
      "common_treatments": [
        "PI/IMiD/steroid regimens",
        "ASCT",
        "Consider venetoclax in trials"
      ]
    },
    {
      "name": "t(4;14) myeloma (FGFR3/MMSET)",
      "typical_patients": "Adults; high-risk cytogenetics",
      "five_year_survival": "≈30–40%",
      "common_treatments": [
        "PI-based therapy (bortezomib-containing)",
        "ASCT",
        "Maintenance strategies"
      ]
    },
    {
      "name": "del(17p)/TP53 myeloma",
      "typical_patients": "Adults; high-risk cytogenetics",
      "five_year_survival": "≈20–30%",
      "common_treatments": [
        "Intensive PI/IMiD regimens",
        "ASCT (selected)",
        "Clinical trials, CAR-T/bispecifics"
      ]
    }
  ],
  "epidemiology": {
    "global_cases_2015": "488000",
    "global_deaths_2015": "101100",
    "most_common_in": "Older adults; more common in men; higher incidence in African Americans",
    "five_year_survival_rate": "≈60% (US, 2013–2019 cohort)"
  },
  "relationships": [
    {
      "source": "Multiple myeloma",
      "relation": "has_symptom",
      "target": "Bone pain"
    },
    {
      "source": "Multiple myeloma",
      "relation": "has_symptom",
      "target": "Anemia"
    },
    {
      "source": "Multiple myeloma",
      "relation": "has_symptom",
      "target": "Renal insufficiency"
    },
    {
      "source": "Multiple myeloma",
      "relation": "has_symptom",
      "target": "Hypercalcemia"
    },
    {
      "source": "Multiple myeloma",
      "relation": "has_symptom",
      "target": "Recurrent infections"
    },
    {
      "source": "Multiple myeloma",
      "relation": "has_cause",
      "target": "IGH translocations"
    },
    {
      "source": "Multiple myeloma",
      "relation": "has_risk_factor",
      "target": "Older age"
    },
    {
      "source": "Multiple myeloma",
      "relation": "has_risk_factor",
      "target": "Obesity"
    },
    {
      "source": "Multiple myeloma",
      "relation": "has_risk_factor",
      "target": "Ionizing radiation exposure"
    },
    {
      "source": "Multiple myeloma",
      "relation": "associated_gene",
      "target": "CCND1"
    },
    {
      "source": "Multiple myeloma",
      "relation": "associated_gene",
      "target": "FGFR3"
    },
    {
      "source": "Multiple myeloma",
      "relation": "associated_gene",
      "target": "NSD2 (WHSC1/MMSET)"
    },
    {
      "source": "Multiple myeloma",
      "relation": "associated_gene",
      "target": "TP53"
    },
    {
      "source": "Multiple myeloma",
      "relation": "associated_gene",
      "target": "KRAS"
    },
    {
      "source": "Multiple myeloma",
      "relation": "associated_gene",
      "target": "NRAS"
    },
    {
      "source": "Multiple myeloma",
      "relation": "treated_with",
      "target": "Bortezomib"
    },
    {
      "source": "Multiple myeloma",
      "relation": "treated_with",
      "target": "Lenalidomide"
    },
    {
      "source": "Multiple myeloma",
      "relation": "treated_with",
      "target": "Daratumumab"
    },
    {
      "source": "Multiple myeloma",
      "relation": "treated_with",
      "target": "Autologous stem cell transplant"
    },
    {
      "source": "Multiple myeloma",
      "relation": "treated_with",
      "target": "CAR-T (idecabtagene vicleucel)"
    },
    {
      "source": "Multiple myeloma",
      "relation": "treated_with",
      "target": "Bispecific antibody (teclistamab)"
    },
    {
      "source": "t(11;14) myeloma (CCND1)",
      "relation": "subtype_of",
      "target": "Multiple myeloma"
    },
    {
      "source": "t(4;14) myeloma (FGFR3/MMSET)",
      "relation": "subtype_of",
      "target": "Multiple myeloma"
    },
    {
      "source": "del(17p)/TP53 myeloma",
      "relation": "subtype_of",
      "target": "Multiple myeloma"
    },
    {
      "source": "Hyperdiploid multiple myeloma",
      "relation": "subtype_of",
      "target": "Multiple myeloma"
    }
  ]
}